✦ LIBER ✦

Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy

✍ Scribed by Michael C. Heinrich; Christopher L. Corless

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 128 KB
Volume: 90
Category: Article
ISSN: 0022-4790
DOI: 10.1002/jso.20230

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Stage IV breast cancer in the era of tar

Stage IV breast cancer in the era of targeted therapy : Does surgery of the primary tumor matter?

✍ Heather B. Neuman; Mary Morrogh; Mithat Gonen; Kimberly J. Van Zee; Monica Morro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 156 KB

Adjuvant and neoadjuvant imatinib therap

Adjuvant and neoadjuvant imatinib therapy: Current role in the management of gastrointestinal stromal tumors

✍ Burton L. Eisenberg; Jonathan C. Trent 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 212 KB

## Abstract Although surgery remains the mainstay for the treatment of primary gastrointestinal stromal tumors (GIST), a significant number of patients experience disease recurrence within 5 years of surgery. The emergence of imatinib therapy for the treatment of patients with advanced GIST has off

The role of Fas ligand and transforming

The role of Fas ligand and transforming growth factor β in tumor progression : Molecular mechanisms of immune privilege via Fas-mediated apoptosis and potential targets for cancer therapy

✍ Ryungsa Kim; Manabu Emi; Kazuaki Tanabe; Yoko Uchida; Tetsuya Toge 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 206 KB

## Abstract Despite the fact that expression of Fas ligand (FasL) in cytotoxic T lymphocytes (CTLs) and in natural killer (NK) cells plays an important role in Fas‐mediated tumor killing, During tumor progression FasL‐expressing tumor cells are involved in __counterattacking__ to kill tumor‐infiltr